RE:Interesting days ahead for ADK...Very good question.
this article was out last summer.
It says that they want to develop new treatment for macular edema and macular degeneration. They are both in the treament of those problems. As we are a detection tool of those eye problems created by diabetes. Further more, our AI system is 98% efficient and very rapid (few minutes) in helping specialists give the right diagnostic.
For Bayer and Noveartis, it's a no brainer to be associated with ADK. They take no risk, and there is no exclusivity.
Right now, i dont think we are part of that joint venture strategy, but part of a strategy to get screening that is cheap, fast and reliable.
WE ARE A DIAGNOSTIC COMPANY.
Dont worry, those companies are very savvy and if they see potential confirmed, they're gonna want to take us out. I just hope it's not gonna be too soon). Especially with the market cap we have right now.
I just wonder how much we would be trading at if we were listed in the US?
The other part that will be more exciting is the cardio risk analysis.... with much bigger market potential. (but that's another story).
That's just my opinion .... for wathever it's worth. Cant wait to read other's comments